( ognizes an epitope of CD44 that ishigh...)ARIUS to Present at American Association for Cancer Research Annual,Meeting,Health

ognizes an epitope of CD44 that is highly expressed in liver cancers. Abstract 662, Section 27, Board 15, Sunday, Apr 15, 8AM - 12PM

ARH460-16-2, a functional antibody that targets CD44, has previously been shown to have anti-tumor and survival benefits in animal models of breast and prostate cancers. New immunohistochemistry (IHC) studies demonstrated high levels of ARH460-16-2 binding to primary liver tumors: 43% (21/49). The antibody also bound more frequently to metastatic than to primary hepatocellular carcinomas, 88% (7/8) versus 30% (11/37), and there was a trend towards higher binding in advanced AJCC stages in comparison with earlier stages: 0% (stage I), 12% (stage II), 50% (stage III) and 75% (stage IV). In vivo studies are currently under way, to assess the therapeutic effect of this antibody in an in vivo model of metastatic hepatocellular carcinoma.

Functional antibodies targeting Trop-2 demonstrate in vivo efficacy in human pancreatic and other solid tumor xenograft models. Abstract 904, Section 5, Board 3, Sunday, Apr 15, 1PM - 5PM

Two monoclonal antibodies directed against Trop-2, AR47A6.4.2 and AR52A301.5, have been independently generated which, in in vitro assays, induce cytotoxicity in pancreatic, colon, lung and ovarian cancer cell lines.

Experiments conducted using the human pancreatic BxPC-3 xenograft model demonstrated that treatment with these antibodies resulted in tumor growth inhibition in both prophylactic and established models. The in vivo anti-tumor efficacy of these antibodies was examined in models of other solid tumor cancer indications, and the anti-tumor effect in human pancreatic cancer was substantiated by a second model of human pancreatic cancer. With the aim of bringing these antibodies to the clinic, the selection of an animal model for toxicology studies was undertaken. Results from these studies have
demonstrated a very similar expression pattern between hum
'"/>




Page: 1 2 3 4
Related medicine technology :

1. The Past, Present and Future of HLA Typing
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
10. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference